查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1620754

月经症候群治疗药物市场：按药物类型、类型和分销管道划分 - 全球预测 2025-2030

Premenstrual Syndrome Treatment Market by Drug Type (Antidepressants, Diuretics, Nonsteroidal Anti-inflammatory Drugs (NSAIDs)), Type (Over-the-Counter, Prescription), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年月经症候群治疗药物市场价值为17.2亿美元，预计到2024年将达到17.9亿美元，复合年增长率为4.35%，到2030年将达到23.2亿美元。

月经症候群 (PMS) 治疗市场围绕着一系列旨在缓解经前症候群 (PMS) 症状的治疗方法和产品展开，经前症候群影响了很大一部分月经人群。经前症候群的广泛流行证明了对这个市场的需求，经前症候群会导致身体、情绪和行为症状，严重影响日常生活和生活品质。经前症候群药物的用途包括非处方药、补充品和改变生活方式，以及解决情绪低落、腹胀和痉挛等特定症状的处方治疗。最终使用者主要是寻求缓解这些症状的个人，包括自我用药的个人和在医生监督下的个人。该市场的成长受到人们意识的提高、女性医疗保健的进步以及对个人化医疗日益增长的偏好的显着影响。开发基于激素的治疗方法、植物来源的治疗方法以及用于症状追踪和管理的数位健康解决方案存在机会。然而，这个市场面临一些限制，例如当前治疗方法的副作用和阻碍公开讨论和诊断的社会耻辱，以及核准新治疗方法的监管挑战。此外，由于经前症候群的多方面性质，没有一刀切的治疗方法，这是一个问题。可以探索非荷尔蒙治疗方案、用于个人化治疗的人工智慧以及增强患者参与度的行动医疗技术等创新。对导致经前症候群的特定遗传、荷尔蒙和生活方式因素的研究可能会为更有针对性的干预措施提供见解。经前症候群治疗市场充满活力，对提供全面症状缓解的有效解决方案的需求持续增长。治疗公司正在利用未满足的需求并透过专注于以患者为中心的方法、进行宣传宣传活动以减少耻辱以及与医疗专业人员合作优化治疗通讯协定来获得市场动力，这可能会导致成长和患者结果的改善。

主要市场统计
基准年[2023] 17.2亿美元
预测年份 [2024] 17.9亿美元
预测年份 [2030] 23.2亿美元
复合年增长率（%） 4.35%

市场动态：快速发展的月经症候群治疗市场的关键市场洞察

供需的动态交互作用正在改变经月经症候群药物的市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 提高月经症候群的诊断意识
    • 透过线上管道轻鬆获得经前症候群治疗产品
  • 市场限制因素
    • 与 PMS 治疗药物和设备产品召回相关的问题
  • 市场机会
    • 经前症候群治疗进展及新药出现
    • 穿戴式科技的采用和数位健康的普及
  • 市场挑战
    • 有关 PMS 管理的社会障碍与污名化

波特五力：驾驭月经症候群药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对月经症候群治疗市场的影响

外部宏观环境因素在塑造月经症候群治疗药物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解月经症候群治疗药物市场的竞争状况

月经症候群治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV月经症候群治疗药物市场定位矩阵供应商绩效评估

FPNV 定位矩阵是评估经月经症候群治疗药物市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划经月经症候群治疗药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对月经症候群治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开发：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 提高对月经症候群相关诊断的认识
      • 透过线上管道轻鬆获得经前症候群治疗产品
    • 抑制因素
      • 与 PMS 药品和设备产品召回相关的问题
    • 机会
      • 经前症候群治疗的进展与新药的出现
      • 穿戴式科技的引入和数位健康的传播
    • 任务
      • 有关经前症候群管理的社会障碍和耻辱
  • 市场区隔分析
    • 药物类型：由于口服避孕药具有避孕和症状管理的双重作用，因此越来越多地用于管理经前症候群症状。
    • 分销管道：由于顾客便捷的购物需求，电子商务分销管道正成为首选。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类型分類的经月经症候群治疗药物市场

  • 抗忧郁症
  • 利尿剂
  • 非类固醇消炎剂(NSAID)
  • 口服避孕药和卵巢抑制剂

第七章月经症候群治疗药物市场：依类型

  • 在商店
  • 处方笺

第八章月经症候群治疗药物市场：按分销管道

  • 电子商务
  • 医院
  • 零售药房

第九章北美和南美月经症候群治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太经月经症候群治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲月经症候群治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Vistagene 宣布 PH80 用于急性管理经月经焦虑症症状的探索性 2A 期研究取得正面结果
    • 三十麦迪逊医院将透过从 The Pill Club 策略收购资产，为数千名患者提供连续性护理，并加强其在女性健康领域的地位。
    • 总部位于伦敦的神经科技Start-Ups开发治疗月经症状的医疗设备
  • 战略分析和建议

公司名单

  • AA Pharma Inc.
  • Alfa Pharma GmbH
  • Asarina Pharma AB.
  • ASKA Pharmaceutical Co., Ltd.
  • Aurobindo Pharma
  • Bayer AG
  • Cadila Pharmaceuticals.
  • Comforte Cream by PMS4PMS, LLC
  • Dr. Reddy's Laboratories Inc.
  • GlaxoSmithKline plc
  • Intas Pharmaceuticals Ltd.
  • Lupin Limited
  • Mylan NV
  • Par Pharmaceutical, Inc
  • Pfizer Inc.
  • Samphire Neuroscience
  • Shine Pharmaceuticals Limited
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • The Himalaya Drug Company
  • Vitane Pharmaceuticals, Inc.
Product Code: MRR-4F1ADAF481D9

The Premenstrual Syndrome Treatment Market was valued at USD 1.72 billion in 2023, expected to reach USD 1.79 billion in 2024, and is projected to grow at a CAGR of 4.35%, to USD 2.32 billion by 2030.

Premenstrual Syndrome (PMS) Treatment Market is centered around the array of therapies and products designed to alleviate symptoms of PMS, which affects a significant proportion of menstruating individuals. The necessity of this market is underscored by the widespread prevalence of PMS, which can cause physical, emotional, and behavioral symptoms, substantially impacting daily activities and quality of life. Applications of PMS treatments span from over-the-counter medications, supplements, and lifestyle modifications to prescription therapies, tailored to address specific symptoms like mood swings, bloating, and cramps. End-users primarily encompass individuals seeking relief from these symptoms, including both those self-treating and those under medical supervision. Growth in this market is significantly influenced by increasing awareness, advances in women's healthcare, and a rising preference for personalized medicine. Opportunities exist in developing hormone-based treatments, plant-based remedies, and digital health solutions for symptom tracking and management. However, the market faces limitations such as side effects of current treatments, and societal stigma that hinders open discussions and diagnosis, coupled with regulatory challenges in approving new therapies. Additionally, the absence of a one-size-fits-all treatment due to the multifaceted nature of PMS presents challenges. Innovations could be explored in non-hormonal treatment options, artificial intelligence for personalized treatments, and mobile health technologies to enhance patient engagement. Research into specific genetic, hormonal, and lifestyle factors that contribute to PMS could offer insights for more targeted interventions. The PMS treatment market is dynamic, with continuous demand for effective solutions that provide comprehensive symptom relief. Businesses have the potential to capitalize on unmet needs by focusing on patient-centric approaches, creating awareness campaigns to reduce stigma, and collaborating with healthcare professionals to optimize treatment protocols, thereby fostering market growth and improving patient outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 1.72 billion
Estimated Year [2024] USD 1.79 billion
Forecast Year [2030] USD 2.32 billion
CAGR (%) 4.35%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Premenstrual Syndrome Treatment Market

The Premenstrual Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing awareness of diagnosis regarding premenstrual syndrome
    • Easy availability of PMS treatment products through online channels
  • Market Restraints
    • Issues associated with product recalls for PMS drugs and devices
  • Market Opportunities
    • Advancements in therapy for PMS and the emergence of novel drugs
    • Adoption of wearable technology and the proliferation of digital health
  • Market Challenges
    • Societal barriers and stigmatization regarding PMS management

Porter's Five Forces: A Strategic Tool for Navigating the Premenstrual Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Premenstrual Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Premenstrual Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Premenstrual Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Premenstrual Syndrome Treatment Market

A detailed market share analysis in the Premenstrual Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Premenstrual Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Premenstrual Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Premenstrual Syndrome Treatment Market

A strategic analysis of the Premenstrual Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Premenstrual Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include AA Pharma Inc., Alfa Pharma GmbH, Asarina Pharma AB., ASKA Pharmaceutical Co., Ltd., Aurobindo Pharma, Bayer AG, Cadila Pharmaceuticals., Comforte Cream by PMS4PMS, LLC, Dr. Reddy's Laboratories Inc., GlaxoSmithKline plc, Intas Pharmaceuticals Ltd., Lupin Limited, Mylan N.V., Par Pharmaceutical, Inc, Pfizer Inc., Samphire Neuroscience, Shine Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., The Himalaya Drug Company, and Vitane Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Premenstrual Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Antidepressants, Diuretics, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), and Oral Contraceptives & Ovarian Suppression Agents.
  • Based on Type, market is studied across Over-the-Counter and Prescription.
  • Based on Distribution Channel, market is studied across E-commerce, Hospitals, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing awareness of diagnosis regarding premenstrual syndrome
      • 5.1.1.2. Easy availability of PMS treatment products through online channels
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with product recalls for PMS drugs and devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in therapy for PMS and the emergence of novel drugs
      • 5.1.3.2. Adoption of wearable technology and the proliferation of digital health
    • 5.1.4. Challenges
      • 5.1.4.1. Societal barriers and stigmatization regarding PMS management
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Emerging utilization of oral contraceptives for managing PMS symptoms due to their dual role in birth control and symptom management
    • 5.2.2. Distribution Channel: Emerging preference for e-Commerce distribution channels due to customer need for convenient shopping
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Premenstrual Syndrome Treatment Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Antidepressants
  • 6.3. Diuretics
  • 6.4. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 6.5. Oral Contraceptives & Ovarian Suppression Agents

7. Premenstrual Syndrome Treatment Market, by Type

  • 7.1. Introduction
  • 7.2. Over-the-Counter
  • 7.3. Prescription

8. Premenstrual Syndrome Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. E-commerce
  • 8.3. Hospitals
  • 8.4. Retail Pharmacies

9. Americas Premenstrual Syndrome Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Premenstrual Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Premenstrual Syndrome Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
    • 12.3.2. Thirty Madison Delivers Continuity Of Care For Thousands Through Strategic Asset Purchase From The Pill Club, Strengthening Its Position In Women's Health
    • 12.3.3. London-Based Neurotech Start-Up Develops Medical Device For Menstrual Symptoms
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AA Pharma Inc.
  • 2. Alfa Pharma GmbH
  • 3. Asarina Pharma AB.
  • 4. ASKA Pharmaceutical Co., Ltd.
  • 5. Aurobindo Pharma
  • 6. Bayer AG
  • 7. Cadila Pharmaceuticals.
  • 8. Comforte Cream by PMS4PMS, LLC
  • 9. Dr. Reddy's Laboratories Inc.
  • 10. GlaxoSmithKline plc
  • 11. Intas Pharmaceuticals Ltd.
  • 12. Lupin Limited
  • 13. Mylan N.V.
  • 14. Par Pharmaceutical, Inc
  • 15. Pfizer Inc.
  • 16. Samphire Neuroscience
  • 17. Shine Pharmaceuticals Limited
  • 18. Sun Pharmaceutical Industries Ltd.
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. The Himalaya Drug Company
  • 21. Vitane Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. PREMENSTRUAL SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PREMENSTRUAL SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PREMENSTRUAL SYNDROME TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES & OVARIAN SUPPRESSION AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023